|1.||Small, Donald: 11 articles (06/2015 - 03/2004)|
|2.||Castro, Maria G: 11 articles (09/2013 - 12/2004)|
|3.||Lowenstein, Pedro R: 11 articles (09/2013 - 12/2004)|
|4.||Liu, Chunyan: 9 articles (10/2011 - 12/2004)|
|5.||Levis, Mark: 8 articles (06/2015 - 03/2004)|
|6.||Candolfi, Marianela: 7 articles (10/2012 - 07/2007)|
|7.||Kantarjian, Hagop: 6 articles (07/2014 - 05/2004)|
|8.||Ravandi, Farhad: 6 articles (07/2014 - 01/2011)|
|9.||Levis, Mark J: 5 articles (07/2015 - 11/2006)|
|10.||Li, Li: 5 articles (06/2015 - 03/2004)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/2010 - "Molecular characterization of the FMS-like tyrosine kinase 3 receptor (FLT3) in cytogenetically normal acute myeloid leukemia (AML) has recently been incorporated into clinical guidelines based on correlations between FLT3 internal tandem duplications (FLT3-ITD) and decreased disease-free and overall survival. "
10/01/2011 - "The aim of this study was to analyze the FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) allelic ratios (AR), number of ITD, ITD length and positions of ITD insertions in de novo acute myeloid leukemia (AML) patients with FLT3-ITD positive, and the relationship between mutant level and therapeutic efficacy. "
01/01/2010 - "This study revealed that approximately 30% of acute myeloid leukemia patients have either KIT or fms-like tyrosine kinase 3 genetic mutations. "
01/01/2009 - "FLT3 (fms-like tyrosine kinase 3) is frequently activated by mutation in acute myeloid leukemia, and is therefore under study as a drug target. "
09/01/2015 - "Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia (AML) patients and is associated with a dismal long-term prognosis. "
04/15/2015 - "An improved understanding of how the signaling pathways [e.g., Fms-like tyrosine kinase 3 (Flt3), PI3K, and signal transducer and activator of transcription (Stat)] are dysregulated by these mutations in Cbl has helped to identify potential targets for therapy of myeloid neoplasms. "
12/01/2011 - "In the present study, we sought to increase the number of tumor-associated dendritic cells (DC) in vivo and tumor antigen presentation by combining VSV treatment with recombinant Fms-like tyrosine kinase 3 ligand (rFlt3L), a growth factor promoting the differentiation and proliferation of DC. "
04/01/2005 - "We report that transfection of 4T1 mammary tumor cells (p53-null) with the dendritic cell (DC) growth factor, fms-like tyrosine kinase 3 ligand (Flt3L), significantly delayed their growth in vivo, resulting in the rejection of 100% of the tumors formed by injection of tumor cells cotransfected with Flt3L and p53. "
02/01/2008 - "Systemic administration of Fms-like tyrosine kinase 3 ligand (FLT3L) has been considered to be a major route of delivery for tumor immunotherapy because expression of its receptor, FLT3, was detected predominantly in hematopoetic progenitor cells. "
12/01/2013 - "Fms-like tyrosine kinase 3 receptor ligand (Flt3L)-based vaccination administered with an adenoviral vector prevents tumor growth of colorectal cancer in a BALB/c mouse model."
11/01/2012 - "Treatment with Fms-like tyrosine kinase 3 ligand reverses lung dendritic cell immunoparalysis and ameliorates zymosan-induced secondary lung injury in mice."
11/01/2012 - "In the present study, we examined the effects of in vivo Fms-like tyrosine kinase 3 ligand (Flt3L) treatment on zymosan (zym)-induced secondary lung injury and dendritic cell (DC) immunoparalysis. "
03/06/2014 - "We found that IDH2(R140Q) can cooperate with overexpression of HoxA9 and Meis1a and with mutations in FMS-like tyrosine kinase 3 (FLT3) to drive acute leukemia in vivo. "
01/01/2014 - "Another such possible target in pediatric acute leukemia is FMS-like tyrosine kinase 3 (FLT3). "
09/01/2011 - "The FMS-like tyrosine kinase 3 (FLT3) is highly expressed in acute leukemias. "
01/01/2011 - "FMS-like tyrosine kinase 3 (FLT3) is a commonly mutated protein in a variety of human acute leukemias. "
03/01/2010 - "Gene expression profiling experiments identified putative downstream MN1 targets, of which FMS-like tyrosine kinase 3 (FLT3) and CD34 were upregulated in both MN1-overexpressing murine leukemias and in pediatric acute leukemias with high MN1 levels. "
|1.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|2.||sorafenib (BAY 43-9006)
|7.||Janus Kinase 2
|8.||Etoposide (VP 16)
|9.||Type II DNA Topoisomerases (Topoisomerase II)
|1.||Hematopoietic Stem Cell Transplantation
|2.||Drug Therapy (Chemotherapy)